Back to search results

Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants

Abroad (travel likely)RecruitingPHASE1

Conditions

SARS-CoV-2 (COVID-19)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Royal Free London Nhs Foundation Trust, London, United Kingdom

    Contact: Study coordinator (Douglas Fink) · douglas.fink@nhs.net
    Contact: Principal Investigator (Douglas Fink)

  • Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

    Contact: Study coordinator (Anna Goodman) · anna.goodman@nhs.net
    Contact: Principal Investigator (Anna Goodman)

  • Imperial College Healthcare NHS Trust, London, United Kingdom

    Contact: Study coordinator (Christopher Chiu) · c.chiu@imperial.ac.uk
    Contact: Study coordinator (Polly Fox-Sheehan) · polly.fox@imperial.ac.uk
    Contact: Principal Investigator (Christopher Chiu)

  • University of Oxford, Oxford, United Kingdom

    Contact: Study coordinator (Helen McShane) · helen.mcshane@ndm.ox.ac.uk
    Contact: Principal Investigator (Helen McShane)

  • University Hospital Southampton Nhs Foundation Trust, Southampton, United Kingdom

    Contact: Study coordinator (Saul Faust) · s.faust@soton.ac.uk
    Contact: Principal Investigator (Saul Faust)
Study leads

  • Christopher Chiu, BMBCh FRCP FRCPath PhD

    Principal Investigator

    Imperial College London

View source on ClinicalTrials.gov(opens in a new tab)